Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has received the Acceptance Notice issued by the National Medical Products Administration of the PRC (the "NMPA"). The investigational new drug (the "IND") application for Phase II clinical trial of Aminolevulinic Acid Hydrochloride Topical Powder (the "Drug") on mild-to-moderate severity Actinic Keratosis (the "AK") of the face and scalp has been accepted. Relevant information is as follows: Drug name: Aminolevulinic Acid Hydrochloride Topical Powder, Registration type: Class 2.4 improved new drug, Application matter: Registration of Clinical Trial of Domestic Production of Pharmaceutical Product, Acceptance No. CXHL2101563GUO, Applicant: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd, Review conclusion: Accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China.